Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Kameda Y, Noguchi Y
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-Ku, Yokohama 241-0815, Japan.
Hepatogastroenterology. 2000 Nov-Dec;47(36):1575-8.
We report a case of advanced gastric carcinoma successfully treated with a combination of irinotecan and cisplatin as neoadjuvant chemotherapy. The patient, a 78-year-old man, had type 2 gastric cancer, which had metastasized to the paraaortic lymph nodes. He was treated with irinotecan, 70 mg on day 1 and day 15, and cisplatin, 80 mg on day 1. The course was repeated every 4 weeks. Two courses of treatment resulted in a marked reduction of both the primary tumor and lymph nodes. Subsequently, the patient underwent curative surgery consisting of total gastrectomy, splenectomy, and D3 lymph node dissection. No surgical complications were observed. On microscopic examination, only a few tumor cells were detected in the granulation tissues of the resected stomach and in the lymph nodes. This would be the first case to demonstrate the effectiveness and the safety of irinotecan and cisplatin used in the neoadjuvant setting for treatment of advanced gastric carcinoma.
我们报告一例晚期胃癌患者，采用伊立替康和顺铂联合方案作为新辅助化疗，治疗取得成功。该患者为一名78岁男性，患有2型胃癌，已转移至腹主动脉旁淋巴结。给予伊立替康治疗，第1天和第15天各70mg，顺铂第1天80mg。每4周重复一个疗程。两个疗程的治疗使原发肿瘤和淋巴结均明显缩小。随后，患者接受了包括全胃切除术、脾切除术和D3淋巴结清扫术在内的根治性手术。未观察到手术并发症。显微镜检查显示，在切除胃的肉芽组织和淋巴结中仅检测到少数肿瘤细胞。这将是首例证明伊立替康和顺铂用于晚期胃癌新辅助治疗的有效性和安全性的病例。
